Drug intelligence / Profile preview

AMNIOAID

Development stage: Unknown
Lead developer: HCT Regenerative
Administration: Topical

Overview

AMNIOAID is a dehydrated human amniotic membrane allograft developed by HCT Regenerative. Classified as a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P), it serves as a biologic scaffold to facilitate wound healing and tissue regeneration. The product functions by providing a structural extracellular matrix along with essential biologic factors, including growth factors and cytokines, which support the body's natural repair processes. It is primarily used in clinical applications requiring tissue repair and healing support, such as chronic wounds or surgical sites, through a non-pharmacologic, product-level mechanism.

Brand names: AMNIOAID
Other names: AMNIOAID Amniotic Membrane AllograftAmnioAid-HCT Regenerative-amniotic membrane allograft-HCT/P-tissue allograft

Beyond the preview

Go deeper on AMNIOAID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMNIOAID.

Explore the full profile